Short Interest in Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) Declines By 54.9%

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY) was the recipient of a significant decline in short interest during the month of July. As of July 31st, there was short interest totaling 28,818 shares, a decline of 54.9% from the July 15th total of 63,921 shares. Currently, 0.0% of the company’s stock are sold short. Based on an average trading volume of 465,929 shares, the days-to-cover ratio is presently 0.1 days.

Chugai Pharmaceutical Price Performance

CHGCY traded down $0.87 on Friday, hitting $21.55. The company had a trading volume of 133,526 shares, compared to its average volume of 226,508. The stock has a market cap of $70.93 billion, a price-to-earnings ratio of 23.42 and a beta of 0.60. The company’s fifty day moving average price is $22.57 and its 200 day moving average price is $25.87. Chugai Pharmaceutical has a 1-year low of $20.27 and a 1-year high of $34.84.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last announced its quarterly earnings results on Friday, July 24th. The company reported $0.22 EPS for the quarter. Chugai Pharmaceutical had a return on equity of 23.71% and a net margin of 35.09%.The company had revenue of $2.14 billion for the quarter, compared to the consensus estimate of $2.38 billion. On average, sell-side analysts forecast that Chugai Pharmaceutical will post 0.96 EPS for the current year.

Wall Street Analysts Forecast Growth

CHGCY has been the topic of several analyst reports. UBS Group lowered shares of Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. The Goldman Sachs Group raised shares of Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research note on Monday, June 15th. Finally, Zacks Research upgraded shares of Chugai Pharmaceutical to a “hold” rating in a report on Friday, May 29th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy”.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based biopharmaceutical company headquartered in Tokyo that focuses on the discovery, development, manufacture and marketing of prescription medicines. The company develops both biologics and small-molecule therapies, with particular emphasis on oncology and immunology as well as treatments for bone and metabolic disorders. Chugai’s activities span the full drug lifecycle from early research and clinical development through regulatory approval, manufacturing and post-marketing support.

Chugai is known for its research-driven approach and its work on monoclonal antibodies and other biologic therapeutics.